Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Liver Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 35 articles: HTML format

Single Articles

September 2021
1. HANAI T, Nishimura K, Miwa T, Maeda T, et al
   Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
   J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
   PubMed     Abstract available
   
   
   
2. TOKUSHIGE K, Ikejima K, Ono M, Eguchi Y, et al
   Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
   J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01796.
   PubMed     Abstract available
   
   
   July 2021
3. LI D, Ding X, Tian D, Xia L, et al
   Reply to: "COVID-19-associated liver injury (COVALI): role of hepatologists".
   J Gastroenterol. 2021 Jul 12. pii: 10.1007/s00535-021-01807.
   PubMed    
   
   
   
4. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
   Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
   J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
   PubMed     Abstract available
   
   
   
5. SUMIDA Y, Yoneda M
   COVID-19-associated liver injury (COVALI): role of hepatologists.
   J Gastroenterol. 2021 Jul 2. pii: 10.1007/s00535-021-01809.
   PubMed    
   
   
   May 2021
6. OKUSAKA T, Ikeda K, Kudo M, Finn R, et al
   Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
   J Gastroenterol. 2021 May 4. pii: 10.1007/s00535-021-01785.
   PubMed     Abstract available
   
   
   March 2021
7. MAK LY, Huang Q, Wong DK, Stamm L, et al
   Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy.
   J Gastroenterol. 2021 Mar 27. pii: 10.1007/s00535-021-01780.
   PubMed     Abstract available
   
   
   
8. NAKATSUKA T, Nakagawa H, Hayata Y, Wake T, et al
   Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
   J Gastroenterol. 2021 Mar 12. pii: 10.1007/s00535-021-01773.
   PubMed     Abstract available
   
   
   
9. HUO TI, Ho SY, Liu PH
   Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal.
   J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01770.
   PubMed    
   
   
   
10. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.
    PubMed    
    
    
    
11. LI D, Ding X, Xie M, Tian D, et al
    COVID-19-associated liver injury: from bedside to bench.
    J Gastroenterol. 2021;56:218-230.
    PubMed     Abstract available
    
    
    February 2021
12. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    PubMed     Abstract available
    
    
    January 2021
13. TERAI S, Buchanan-Hughes A, Ng A, Lee IH, et al
    Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    J Gastroenterol. 2021 Jan 26. pii: 10.1007/s00535-021-01759.
    PubMed     Abstract available
    
    
    
14. TATEISHI R, Matsumura T, Okanoue T, Shima T, et al
    Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
    J Gastroenterol. 2021 Jan 11. pii: 10.1007/s00535-020-01754.
    PubMed     Abstract available
    
    
    
15. KUDO M, Tsuchiya K, Kato N, Hagihara A, et al
    Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
    J Gastroenterol. 2021 Jan 3. pii: 10.1007/s00535-020-01753.
    PubMed     Abstract available
    
    
    
16. HARADA M
    Diagnosis for Wilson disease: this disease may not be a rare disease.
    J Gastroenterol. 2021;56:114-115.
    PubMed    
    
    
    
17. GARCIA-VILLARREAL L, Hernandez-Ortega A, Sanchez-Monteagudo A, Pena-Quintana L, et al
    Wilson disease: revision of diagnostic criteria in a clinical series with great genetic homogeneity.
    J Gastroenterol. 2021;56:78-89.
    PubMed     Abstract available
    
    
    
18. JIANG L, Starkel P, Fan JG, Fouts DE, et al
    The gut mycobiome: a novel player in chronic liver diseases.
    J Gastroenterol. 2021;56:1-11.
    PubMed     Abstract available
    
    
    December 2020
19. OCHI H, Hiraoka A, Hirooka M, Koizumi Y, et al
    Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    J Gastroenterol. 2020 Dec 5. pii: 10.1007/s00535-020-01747.
    PubMed     Abstract available
    
    
    November 2020
20. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available
    
    
    
21. SUZUKI K, Suda G, Yamamoto Y, Furuya K, et al
    Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
    J Gastroenterol. 2020 Nov 19. pii: 10.1007/s00535-020-01750.
    PubMed     Abstract available
    
    
    October 2020
22. YU WL, Yu G, Dong H, Chen K, et al
    Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2020 Oct 21. pii: 10.1007/s00535-020-01729.
    PubMed     Abstract available
    
    
    
23. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    PubMed     Abstract available
    
    
    
24. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available
    
    
    September 2020
25. YIP TC, Lai JC, Wong GL
    Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    J Gastroenterol. 2020 Sep 24. pii: 10.1007/s00535-020-01726.
    PubMed     Abstract available
    
    
    
26. HIRAMINE Y, Uto H, Mawatari S, Kanmura S, et al
    Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    J Gastroenterol. 2020 Sep 21. pii: 10.1007/s00535-020-01727.
    PubMed     Abstract available
    
    
    August 2020
27. UCHIDA Y, Uemura H, Yamaba S, Hamada D, et al
    Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19.
    J Gastroenterol. 2020 Aug 9. pii: 10.1007/s00535-020-01717.
    PubMed     Abstract available
    
    
    
28. MARASCO G, Serenari M, Renzulli M, Alemanni LV, et al
    Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.
    J Gastroenterol. 2020 Aug 3. pii: 10.1007/s00535-020-01711.
    PubMed     Abstract available
    
    
    July 2020
29. TANAKA H, Okamoto K, Sato Y, Tanaka T, et al
    Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
    J Gastroenterol. 2020 Jul 14. pii: 10.1007/s00535-020-01705.
    PubMed     Abstract available
    
    
    June 2020
30. LIANG LY, Wong VW, Toyoda H, Tse YK, et al
    Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    J Gastroenterol. 2020 Jun 17. pii: 10.1007/s00535-020-01700.
    PubMed     Abstract available
    
    
    
31. SAWADA Y, Shiraki M, Iwasa M, Hiraoka A, et al
    The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study.
    J Gastroenterol. 2020 Jun 12. pii: 10.1007/s00535-020-01694.
    PubMed     Abstract available
    
    
    May 2020
32. SAKAIDA I, Terai S, Kurosaki M, Okada M, et al
    Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    J Gastroenterol. 2020 May 9. pii: 10.1007/s00535-020-01691.
    PubMed     Abstract available
    
    
    March 2020
33. KAWAGUCHI T, Torimura T
    Is metabolic syndrome responsible for the progression from NAFLD to NASH in non-obese patients?
    J Gastroenterol. 2020;55:363-364.
    PubMed    
    
    
    December 2019
34. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    PubMed     Abstract available
    
    
    May 2019
35. NAGANUMA M, Sugimoto S, Suzuki H, Matsuno Y, et al
    Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
    J Gastroenterol. 2019 May 17. pii: 10.1007/s00535-019-01591.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: